News | March 24, 2026
Bayer wins world-first nod in Japan for low-dose MRI contrast agent
Call it a major breakthrough for diagnostic imaging
Call it a major breakthrough for diagnostic imaging
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Subscribe To Our Newsletter & Stay Updated
